Literature DB >> 25493250

Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors.

Christine S Landry1, Keith Cavaness1, Scott Celinski1, John Preskitt1.   

Abstract

Pancreatic neuroendocrine tumors (PNETs) and small bowel neuroendocrine tumors (SBNETs) are rare tumors that are frequently diagnosed late in the course of the disease. Several biomarkers have been proposed in the literature as prognostic factors for patients with these tumors. This article discusses a recent publication in Annals of Surgical Oncology from the University of Iowa analyzing the effect of different biomarkers on survival in patients with PNETs and SBNETs.

Entities:  

Keywords:  5-hydroxyindoleacetic acid (5-HIAA); Pancreatic neuroendocrine tumors (PNETs); chromogranin A (CgA); neurokinin A; neuron specific enolase; pancreastatin; pancreatic polypeptide; serotonin; small bowel neuroendocrine tumors (SBNETs)

Year:  2014        PMID： 25493250      PMCID： PMC4244501          DOI： 10.3978/j.issn.2227-684X.2014.10.01

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


  20 in total

1.  NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.

Authors:  Aaron I Vinik; Eugene A Woltering; Richard R P Warner; Martyn Caplin; Thomas M O'Dorisio; Gregory A Wiseman; Domenico Coppola; Vay Liang W Go
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.

Authors:  Dermot O'Toole; Ashley Grossman; David Gross; Gianfranco Delle Fave; Jaroslava Barkmanova; Juan O'Connor; Ulrich-Frank Pape; Ursula Plöckinger
Journal:  Neuroendocrinology       Date:  2009-08-28       Impact factor: 4.914

Review 3.  Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.

Authors:  Irvin M Modlin; Bjorn I Gustafsson; Steven F Moss; Marianne Pavel; Apostolos V Tsolakis; Mark Kidd
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

4.  Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.

Authors:  Thomas M O'Dorisio; Siegfried R Krutzik; Eugene A Woltering; Erika Lindholm; Saju Joseph; Abby E Gandolfi; Yi-Zarn Wang; J Phillip Boudreaux; Aaron I Vinik; Vay Liang W Go; James R Howe; Thor Halfdanarson; M Sue O'Dorisio; Gregg Mamikunian
Journal:  Pancreas       Date:  2010-07       Impact factor: 3.327

5.  Serum peptide profiles in patients with carcinoid tumors.

Authors:  Kristine Calhoun; SuEllen Toth-Fejel; Julie Cheek; Rodney Pommier
Journal:  Am J Surg       Date:  2003-07       Impact factor: 2.565

6.  A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.

Authors:  R L Stronge; G B Turner; B T Johnston; D R McCance; A McGinty; C C Patterson; J E S Ardill
Journal:  Ann Clin Biochem       Date:  2008-09-09       Impact factor: 2.057

7.  Source of plasma chromogranin A elevation in gastrinoma patients.

Authors:  B E Stabile; T J Howard; E Passaro; D T O'Connor
Journal:  Arch Surg       Date:  1990-04

8.  Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.

Authors:  G B Turner; B T Johnston; D R McCance; A McGinty; R G P Watson; C C Patterson; J E S Ardill
Journal:  Gut       Date:  2006-03-23       Impact factor: 23.059

9.  Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease.

Authors:  R S Carling; T J Degg; K R Allen; N D S Bax; J H Barth
Journal:  Ann Clin Biochem       Date:  2002-11       Impact factor: 2.057

10.  Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.

Authors:  E Baudin; A Gigliotti; M Ducreux; J Ropers; E Comoy; J C Sabourin; J M Bidart; A F Cailleux; R Bonacci; P Ruffié; M Schlumberger
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640
View more
  5 in total

1.  Analysis of the factors affecting lymph node metastasis and the prognosis of rectal neuroendocrine tumors.

Authors:  Peng Li; Fan Wu; Hong Zhao; Lizhou Dou; Yang Wang; Chunguang Guo; Guiqi Wang; Dongbing Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors.

Authors:  Guopei Luo; Chen Liu; He Cheng; Kaizhou Jin; Meng Guo; Yu Lu; Jiang Long; Jin Xu; Quanxing Ni; Jie Chen; Xianjun Yu
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

3.  Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.

Authors:  Yu Zhou; Dezhi Li; Ye Lin; Min Yu; Xin Lu; Zhixiang Jian; Ning Na; Baohua Hou
Journal:  Onco Targets Ther       Date:  2018-05-01       Impact factor: 4.147

4.  Neuroendocrine Neoplasms: Identification of Novel Metabolic Circuits of Potential Diagnostic Utility.

Authors:  Beatriz Jiménez; Mei Ran Abellona U; Panagiotis Drymousis; Michael Kyriakides; Ashley K Clift; Daniel S K Liu; Eleanor Rees; Elaine Holmes; Jeremy K Nicholson; James M Kinross; Andrea Frilling
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

5.  Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine.

Authors:  Małgorzata Fuksiewicz; Maria Kowalska; Agnieszka Kolasińska-Ćwikła; Jarosław B Ćwikła; Łukasz Sawicki; Katarzyna Roszkowska-Purska; Joanna Drygiel; Beata Kotowicz
Journal:  Endocr Connect       Date:  2018-05-03       Impact factor: 3.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.